INmune Bio Reports First Patient Dosing in P-II (XPro1595) Trial for the Treatment of Neuroinflammation in Patients with Alzheimer Disease
Shots:
- The first patient has been enrolled in P-II (XPro1595/ XPro Study) trial to evaluate XPro in a ratio (2:1) in 201 patients with mild AD & biomarkers of inflammation in Australia, Canada & the US
- After participating in the 6mos. P-II trial, patients will be eligible for an extension trial & continuous monitoring of biomarkers of inflammation & cognition for 12mos. In the P-I study, the results showed an improvement in multiple biomarkers, reduction in neuroinflammation & neurodegeneration along with an improvement in biomarkers of neuro repair & neuron communication
- The company is planning for a second P-II trial in patients with MCI. The results from both clinical trials are expected in 2023
Ref: Globe Newswire | Image: Inmune bio
Click here to read the full press release
Neha is a Senior Editor at PharmaShots. She is passionate and very enthusiastic about recent updates and developments in the life sciences and pharma industry. She covers Biopharma, MedTech, and Digital health segments along with different reports at PharmaShots. She can be contacted at connect@pharmashots.com.
